Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction

Liver International

Volumn 31, Issue 9, 2011, Pages 1315-1324

  Jun, Dae Won ^a   Cho, Won Kyeong ^b   Jun, Jin Hyun ^c   Kwon, Hyuk Jin ^b   Jang, Ki Seok ^a   Kim, Hyun Jeong ^a   Jeon, Hye Jun ^a   Lee, Kang Nyeong ^a   Lee, Hang Lak ^a   Lee, Oh Young ^a   Yoon, Byung Chul ^a   Choi, Ho Soon ^a   Hahm, Joon Soo ^a   Lee, Min Ho ^a  

^a Hanyang University   (South Korea)

^b Celltrion Pharma   (South Korea)

^c Eulji University   (South Korea)

Author keywords

Carnitine; Lipotoxicity; Mitochondria

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; FATTY ACID; MESSENGER RNA; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DENSITY; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIPID OXIDATION; LIPOTOXICITY; LIVER TOXICITY; LYSOSOME; MEMBRANE POTENTIAL; MITOCHONDRION; MORPHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION KINETICS; OXIDATIVE STRESS; RAT; ULTRASTRUCTURE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; LIVER; LYSOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; METHIONINE; MITOCHONDRIA, LIVER; OXIDATION-REDUCTION; OXIDATIVE STRESS; PPAR GAMMA; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; RNA, MESSENGER; THIOCTIC ACID; TIME FACTORS;

EID: 80052543705     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02602.x     Document Type: Article

References (28)

1. Wong J, Mclennan SV, Molyneaux L, et al. Mitochondrial DNA content in peripheral blood monocytes: relationship with age of diabetes onset and diabetic complications. Diabetologia 2009; 52: 1953-61.
2. Weng SW, Lin TK, Liou CW, et al. Peripheral blood mitochondrial DNA content and dysregulation of glucose metabolism. Diabetes Res Clin Pract 2009; 83: 94-99.
3. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
5. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
6. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
7. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-40.
8. Murosaki S, Lee TR, Muroyama K, et al. A combination of caffeine, arginine, soy isoflavones, and L-carnitine enhances both lipolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in vitro and in KK mice in vivo. J Nutr 2007; 137: 2252-7.
9. Lin X, Shim K, Odle J. Carnitine palmitoyltransferase I control of acetogenesis, the major pathway of fatty acid {beta}-oxidation in liver of neonatal swine. Am J Physiol Regul Integr Comp Physiol 2010; 298: 1435-43.
10. Westin MA, Hunt MC, Alexson SE. Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of beta-oxidation products out of peroxisomes. Cell Mol Life Sci 2008; 65: 982-90.
11. Sachan DS, Rhew TH, Ruark RA. Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver. Am J Clin Nutr 1984; 39: 738-44.
12. Malaguarnera M, Gargante MP, Russo C, et al. L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338-45.
13. Lim CY, Jun DW, Jang SS, et al. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. Korean J Gastroenterol 2010; 55: 384-9.
14. Park KS, Lee KU, Song JH, et al. Peripheral blood mitochondrial DNA content is inversely correlated with insulin secretion during hyperglycemic clamp studies in healthy young men. Diabetes Res Clin Pract 2001; 52: 97-102.
15. Yu E. Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases. Taehan Kan Hakhoe Chi 2003; 9: 42-46.
16. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-7.
17. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
19. Kuratsune H, Yamaguti K, Lindh G, et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med 1998; 2: 51-56.
20. Romano M, Vacante M, Cristaldi E, et al. L-Carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci 2008; 53: 1114-21.
21. Li Z, Berk M, Mcintyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008; 47: 1495-503.
22. Ruggenenti P, Van Der Meer IM, Remuzzi G. Oral acetyl-L-carnitine therapy and insulin resistance. Hypertension 2010; 55: e26.
23. Muniyappa R. Oral carnitine therapy and insulin resistance. Hypertension 2010; 55: e13.
24. Noland RC, Woodlief TL, Whitfield BR, et al. Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance. Am J Physiol Endocrinol Metab 2007; 293: E986-E1001.
25. Romestaing C, Piquet MA, Bedu E, et al. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond) 2007; 4: 4.
26. Ota T, Takamura T, Kurita S, et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-93.
27. Bene J, Csiky B, Komlosi K, Sulyok E, Melegh B. Dynamic adaptive changes of the serum carnitine esters during and after L-carnitine supplementation in patients with maintenance haemodialysis. Scand J Clin Lab Invest 2011. Mar 3 (Epub ahead of print).
28. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006; 32: 551-9.